Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Pertuzumab/ trastuzumab (Phesgo) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab